|
US4271068A
(en)
|
1968-05-10 |
1981-06-02 |
Ciba-Geigy Corporation |
Process for the manufacture of cystine-containing peptides
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4033940A
(en)
|
1975-11-12 |
1977-07-05 |
Armour Pharmaceutical Company |
Cyclization of peptides
|
|
US4216141A
(en)
|
1978-07-19 |
1980-08-05 |
The Salk Institute For Biological Studies |
Method for cyclization of peptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
NZ199722A
(en)
|
1981-02-25 |
1985-12-13 |
Genentech Inc |
Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5371109A
(en)
|
1986-07-01 |
1994-12-06 |
Drilletten Ab |
Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
FR2641081A1
(cg-RX-API-DMAC7.html)
*
|
1988-12-23 |
1990-06-29 |
Medgenix Group |
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
KR0185192B1
(ko)
|
1989-10-05 |
1999-04-01 |
제임스 더블유. 데이비 |
신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
|
|
US5585353A
(en)
|
1990-02-02 |
1996-12-17 |
The Rockefeller University |
Antibiotic peptides containing D-amino acids
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US5766897A
(en)
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
|
US5843701A
(en)
|
1990-08-02 |
1998-12-01 |
Nexstar Pharmaceticals, Inc. |
Systematic polypeptide evolution by reverse translation
|
|
US5270170A
(en)
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
AU684510B2
(en)
|
1993-05-28 |
1997-12-18 |
Chiron Corporation |
Method for selection of biologically active peptide sequences
|
|
DK0710243T3
(da)
|
1993-06-29 |
2000-10-16 |
Ferring Bv |
Syntese af cykliske peptider
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
US6037453A
(en)
*
|
1995-03-15 |
2000-03-14 |
Genentech, Inc. |
Immunoglobulin variants
|
|
US5834318A
(en)
|
1995-05-10 |
1998-11-10 |
Bayer Corporation |
Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
|
|
US5912014A
(en)
|
1996-03-15 |
1999-06-15 |
Unigene Laboratories, Inc. |
Oral salmon calcitonin pharmaceutical products
|
|
US6720472B2
(en)
|
1996-07-12 |
2004-04-13 |
University Of Medicine And Dentistry Of New Jersey |
HMGI proteins in cancer and obesity
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
EP1477561B1
(en)
|
1996-10-17 |
2008-12-10 |
Mitsubishi Chemical Corporation |
Molecule assigning genotype to phenotype and use thereof
|
|
US6348584B1
(en)
|
1996-10-17 |
2002-02-19 |
John Edward Hodgson |
Fibronectin binding protein compounds
|
|
US5922680A
(en)
|
1996-10-23 |
1999-07-13 |
Ferring, B.V. |
Stabilized composition for oral administration of peptides
|
|
WO1998031700A1
(en)
|
1997-01-21 |
1998-07-23 |
The General Hospital Corporation |
Selection of proteins using rna-protein fusions
|
|
US6261804B1
(en)
|
1997-01-21 |
2001-07-17 |
The General Hospital Corporation |
Selection of proteins using RNA-protein fusions
|
|
US5990237A
(en)
|
1997-05-21 |
1999-11-23 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
|
|
DE69839147T2
(de)
|
1997-06-12 |
2009-02-19 |
Novartis International Pharmaceutical Ltd. |
Künstliche antikörperpolypeptide
|
|
EP0896001A1
(en)
|
1997-08-08 |
1999-02-10 |
Daicel Chemical Industries, Ltd. |
Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
|
|
US6429301B1
(en)
|
1998-04-17 |
2002-08-06 |
Whitehead Institute For Biomedical Research |
Use of a ribozyme to join nucleic acids and peptides
|
|
JP4430235B2
(ja)
|
1998-08-07 |
2010-03-10 |
エミスフェアー・テクノロジーズ・インク |
活性剤のデリバリーのための化合物及び組成物
|
|
AU6059099A
(en)
*
|
1998-09-25 |
2000-04-17 |
Children's Medical Center Corporation |
Short peptides which selectively modulate the activity of protein kinases
|
|
WO2000021559A2
(en)
|
1998-10-09 |
2000-04-20 |
Musc Foundation For Research Development |
Blocking factor b to treat complement-mediated immune disease
|
|
US6962781B1
(en)
|
2000-05-19 |
2005-11-08 |
Proteonova, Inc. |
In vitro evolution of nucleic acids and encoded polypeptide
|
|
US7244701B2
(en)
|
2000-06-16 |
2007-07-17 |
Zealand Phama A/S |
Diuretic peptide conjugate
|
|
US20030232014A1
(en)
*
|
2002-03-01 |
2003-12-18 |
Mds Proteomics Inc. |
Phosphorylated proteins and uses related thereto
|
|
US7411039B2
(en)
*
|
2002-10-14 |
2008-08-12 |
Novo Nordisk A/S |
GLP-2 compounds, formulations, and uses thereof
|
|
CA2505601C
(en)
*
|
2002-11-15 |
2014-10-28 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
|
DE602004026712D1
(de)
*
|
2003-05-05 |
2010-06-02 |
Probiodrug Ag |
Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
|
|
ES2522525T3
(es)
|
2003-05-15 |
2014-11-14 |
Genentech, Inc. |
Métodos y composiciones para la prevención y el tratamiento de la sepsis
|
|
CA2579635A1
(en)
|
2003-09-10 |
2005-03-17 |
Baxter International Inc. |
Peptides that inhibit complement activation
|
|
EP1706098A4
(en)
|
2003-11-26 |
2012-08-15 |
Supernus Pharmaceuticals Inc |
MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
|
|
US7803931B2
(en)
*
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
US20060027059A1
(en)
|
2004-08-09 |
2006-02-09 |
Chih-Ching Hsien |
Extendable handle device
|
|
US20090054623A1
(en)
*
|
2004-12-17 |
2009-02-26 |
Neose Technologies, Inc. |
Lipo-Conjugation of Peptides
|
|
CA2595902C
(en)
|
2005-01-24 |
2017-08-22 |
Pepscan Systems B.V. |
Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors
|
|
WO2006105214A2
(en)
|
2005-03-29 |
2006-10-05 |
Cardax Pharmaceuticals, Inc. |
Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
|
|
JP5707024B2
(ja)
|
2005-05-26 |
2015-04-22 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ |
外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
|
|
ES2399645T3
(es)
|
2005-06-06 |
2013-04-02 |
Camurus Ab |
Formulaciones de análogos de GLP-1
|
|
NZ567483A
(en)
|
2005-11-04 |
2012-04-27 |
Genentech Inc |
Use of complement pathway inhibitors to treat ocular diseases
|
|
AU2007225044C1
(en)
|
2006-03-15 |
2018-03-29 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
|
EP1876183A1
(en)
*
|
2006-07-04 |
2008-01-09 |
Technische Universität München |
Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
|
|
HUE026042T2
(en)
|
2006-10-10 |
2016-05-30 |
Regenesance B V |
Complement inhibition for improved nerve regeneration
|
|
US7736860B2
(en)
|
2006-11-09 |
2010-06-15 |
Univeristy Of Massachusetts |
Methods of identifying compounds for the treatment of sterile inflammation
|
|
WO2008109742A1
(en)
|
2007-03-06 |
2008-09-12 |
Novo Nordisk A/S |
Modulation of complement system activation for treatment of bleeding-related inflammation
|
|
CN101679486A
(zh)
|
2007-03-22 |
2010-03-24 |
诺瓦提斯公司 |
C5抗原及其用途
|
|
US20100015139A1
(en)
|
2008-07-10 |
2010-01-21 |
Rekha Bansal |
METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
|
|
KR20100014486A
(ko)
|
2007-04-30 |
2010-02-10 |
알콘 리서치, 리미티드 |
보체 인자 ｄ의 저해제를 사용한 연령 관련 황반변성의 치료
|
|
SG10201608952QA
(en)
|
2007-06-07 |
2016-12-29 |
Genentech Inc |
C3b antibodies and methods for the prevention and treatment of complement- associated disorders
|
|
US20110142837A1
(en)
|
2007-07-20 |
2011-06-16 |
Trustees Of The University Of Pennsylvania |
Method Of Treating Acute Respiratory Distress Syndrome
|
|
RU2505311C2
(ru)
|
2007-10-02 |
2014-01-27 |
Потентия Фармасьютикалз, Инк. |
Пролонгированная доставка аналогов компстатина из гелей
|
|
WO2009067191A2
(en)
|
2007-11-16 |
2009-05-28 |
The General Hospital Corporation |
Methods and compositions for the treatment of hepatitis c virus (hcv) infection
|
|
EP2278987A4
(en)
|
2008-03-28 |
2012-08-22 |
Apellis Ag |
MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
|
|
WO2010014830A2
(en)
|
2008-07-30 |
2010-02-04 |
Cosmix Therapeutics Llc |
Peptide therapeutics that bind vegf and methods of use thereof
|
|
PL2328616T3
(pl)
*
|
2008-08-05 |
2015-10-30 |
Novartis Ag |
Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5
|
|
WO2010025510A1
(en)
|
2008-09-03 |
2010-03-11 |
Xenome Ltd |
Libraries of peptide conjugates and methods for making them
|
|
BRPI0921237A2
(pt)
|
2008-11-10 |
2015-09-22 |
Alexion Pharma Inc |
métodos e composições para o tratamento de distúrbios associados ao complemento
|
|
AU2009230735B1
(en)
|
2009-01-08 |
2010-01-21 |
Shane Ramodien |
Electronic equipment housing
|
|
PT2488203T
(pt)
|
2009-10-16 |
2017-03-10 |
Univ Leicester |
Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
|
|
NZ600393A
(en)
*
|
2009-11-05 |
2014-08-29 |
Alexion Cambridge Corp |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
CN102791731B
(zh)
|
2009-12-16 |
2016-04-20 |
诺沃—诺迪斯克有限公司 |
Glp-1类似物和衍生物
|
|
US9172511B2
(en)
|
2009-12-24 |
2015-10-27 |
Samsung Electronics Co., Ltd. |
Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
|
|
US9358266B2
(en)
|
2010-02-25 |
2016-06-07 |
The Trustees Of The University Of Pennsylvania |
Treatment of sepsis using complement inhibitors
|
|
WO2011112999A2
(en)
*
|
2010-03-12 |
2011-09-15 |
The Regents Of The University Of California |
Lipid-peptide-polymer conjugates and nanoparticles thereof
|
|
WO2011139343A2
(en)
*
|
2010-04-28 |
2011-11-10 |
Wu Nian |
Amino acid linked peg-lipid conjugates
|
|
EP2563359A1
(en)
|
2010-04-30 |
2013-03-06 |
Allergan, Inc. |
Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
|
|
TW201241008A
(en)
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
|
AP2013007173A0
(en)
*
|
2011-03-16 |
2013-10-31 |
Amgen Inc |
Potent and selective inhibitors of NAV1.3 and NAV1.7
|
|
MX381987B
(es)
|
2011-04-08 |
2025-03-13 |
Univ Leicester |
El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2
|
|
WO2012162215A1
(en)
|
2011-05-20 |
2012-11-29 |
The Trustees Of The University Of Pennsylvania |
Promotion of fracture healing using complement inhibitors
|
|
WO2012174055A1
(en)
|
2011-06-13 |
2012-12-20 |
The Trustees Of The University Of Pennsylvania |
Wound healing using complement inhibitors
|
|
CN102321170B
(zh)
*
|
2011-09-14 |
2013-11-13 |
深圳翰宇药业股份有限公司 |
利拉鲁肽变构体及其缀合物
|
|
US20140296147A1
(en)
*
|
2011-10-06 |
2014-10-02 |
The Medicines Company |
Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
|
|
ES2715638T3
(es)
*
|
2012-02-20 |
2019-06-05 |
Swedish Orphan Biovitrum Ab Publ |
Polipéptidos que se unen al complemento humano C5
|
|
US20130246083A1
(en)
|
2012-03-16 |
2013-09-19 |
Alexion Pharmaceuticals, Inc. |
Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
|
|
WO2013172954A1
(en)
|
2012-05-17 |
2013-11-21 |
Ra Pharmaceuticals, Inc |
Peptide and peptidomimetic inhibitors
|
|
US9579360B2
(en)
|
2012-06-20 |
2017-02-28 |
The Trustees Of The University Of Pennsylvania |
Methods of treating or preventing periodontitis and diseases associated with periodontitis
|
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
WO2014078622A1
(en)
|
2012-11-15 |
2014-05-22 |
The Brigham And Women's Hospital, Inc. |
Method and system for diagnosing and treating preeclampsia
|
|
US9700633B2
(en)
*
|
2013-01-28 |
2017-07-11 |
Jenkem Technology Co., Ltd., Tianjin Branch |
Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
|
|
GB201301632D0
(en)
*
|
2013-01-30 |
2013-03-13 |
Imp Innovations |
Complement System
|
|
US20140234275A1
(en)
|
2013-02-15 |
2014-08-21 |
Jason Williams |
Method for treating als via the increased production of factor h
|
|
US20150057342A1
(en)
|
2013-08-21 |
2015-02-26 |
Cannabics Pharmaceuticals Inc |
Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
|
|
JP6718379B2
(ja)
|
2014-03-20 |
2020-07-08 |
インフラルクス ゲーエムベーハー |
ウイルス性肺炎治療のためのＣ５ａの阻害剤
|
|
ES2895029T3
(es)
|
2014-06-12 |
2022-02-17 |
Ra Pharmaceuticals Inc |
Modulación de actividad del complemento
|
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
EP3142656B1
(en)
|
2015-01-21 |
2018-10-17 |
Pacira Pharmaceuticals, Inc. |
Multivesicular liposome formulations of tranexamic acid
|
|
RS62630B9
(sr)
*
|
2015-01-28 |
2022-04-29 |
Ra Pharmaceuticals Inc |
Modulatori aktivnosti komplementa
|
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
PL3685847T3
(pl)
|
2015-12-16 |
2023-05-08 |
Ra Pharmaceuticals, Inc. |
Modulatory aktywności dopełniacza
|
|
JP7301741B2
(ja)
|
2016-12-07 |
2023-07-03 |
ラ ファーマシューティカルズ インコーポレイテッド |
補体活性のモジュレータ
|
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
|
EP3682016A4
(en)
|
2017-09-11 |
2021-06-02 |
RA Pharmaceuticals, Inc. |
FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS
|
|
MX2020005547A
(es)
|
2017-12-04 |
2020-08-20 |
Ra Pharmaceuticals Inc |
Moduladores de la actividad del complemento.
|
|
CN113543796A
(zh)
|
2019-03-08 |
2021-10-22 |
Ra制药公司 |
齐鲁考普作为深层组织穿透性c5抑制剂
|
|
EP3958842A1
(en)
|
2019-04-24 |
2022-03-02 |
RA Pharmaceuticals, Inc. |
Compositions and methods for modulating complement activity
|